An interventional study of CPAP-withdrawal and Test Sequence in Excessive Daytime Sleepiness, Obstructive Sleep Apnea (OSA) and CPAP Treatment, sponsored by Stefan Lakämper. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Stefan Lakämper · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Disorders of Excessive Somnolence with a site in Switzerland — 2 open to participants now, 2 under way, none of them phase 3. Disorders of Excessive Somnolence · Switzerland.
Among the 11 studies in Disorders of Excessive Somnolence with a site in Switzerland, this one is the only one that started in 2025, is one of 4 with no phase, and was the 11th registered.
196 studies on the registry are indexed under Disorders of Excessive Somnolence; 34 are open to participants now.
Browse Disorders of Excessive Somnolence studies →2 of the 11 studies in Disorders of Excessive Somnolence with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 10–70 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 30 Disorders of Excessive Somnolence studies recruiting now, 12 (40%) set no upper age limit and 17 (57%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 86 across 158 interventional studies indexed under Disorders of Excessive Somnolence.
Median enrollment 54 across the 9 interventional studies, 360 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 8 most frequent:
Stefan Lakämper is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Stefan Lakämper has 1 study filed under Disorders of Excessive Somnolence — fewer than ten, so there is no comparison to draw.
1 of the studies in Disorders of Excessive Somnolence with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872593Stefan LakämperValidating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Disorders of Excessive Somnolence with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. The proposed test offers higher ecological validity and might complement somnological tests that are standard, but rarely performed. Thus, the test might provide traffic medicine and sonologists with an effective tool, that can also directly convey the risks of excessive daytime sleepiness to drivers and thus, in combination, effectively aid in traffic medicine's mandate to avoid preventable road fatalities.
Excessive daytime sleepiness (EDS) is a symptomatic condition resulting from too little or compromised sleep, caused by psycho-social stress (shiftwork, lifestyle) or medical conditions (obstructive sleep apnoea (OSA), narcolepsy). Driving with untreated EDS might lead to sleepy/drowsy driving and microsleep, which is considered to be one of the highest-ranking causes of road accidents. Sleepiness and its dangers on the wheel might subjectively not be registered by the affected drivers. Also, subjective sleepiness might not correlate with somnological measurements that are also crucial for legally determining the fitness to drive (FTD).
There exists a variety of partially complementary tools to evaluate the extent of EDS. Mean sleep latency obtained in the maintenance of wakefulness test (MWT) is widely, but not uniformly, considered to be one of the most objective measures to evaluate EDS, especially in the context of driving performance. However, there is inconsistent or insufficient evidence for MWTs to reliably predict the FTD in general, potentially as its result might be strongly influenced by motivation. Moreover, patients might not relate low mean MWT-latencies to their own and other's risks in traffic.
A need for improved tools to measure EDS was formulated. It remains open, whether the MWT should be replaced or complemented by, for example, future road-side metabolomics-tests detecting sleepiness in traffic or whether the MWT should be adapted to better convey a.) the risks of EDS in traffic and b.) its meaning for the determination of the FTD.
With this need in mind the investigators proposed furnishing the maintenance of wakefulness test with improved ecological validity to provide an improved tool for the assessment of the effect of excessive daytime sleepiness on the fitness to drive: recently published results from an exploratory feasibility study suggested it to be well possible to transfer the MWT-paradigm to a driving simulator (DS) with high user acceptance. The published result's implication and relevance was well received: the new test, DS-MWT, might complement somnological MWTs in pneumology and neurology. I might provide a naturalistic and relatable tool to determine EDS in traffic medicine, who is institutionally responsible for determining the FTD. This is also desirable, because prohibitively high cost - in time, money and instrumentation - often prevent a standard MWT in standard care of sleep-related medical conditions. Potentially, the use of the DS-MWT might help reduce the number of preventable road fatalities by more often identifying sleepy individuals before they get behind the wheel.
However, for this goal to be achieve, it remains to be evaluated whether the latencies obtained in classical or simulation conditions are comparable and whether obtained latencies actually reflect other clinical parameters of EDS relating to underlying medical conditions, such as for example OSA. This represents a significant gap of evidence for both medical experts in pneumology and traffic medicine, but also for affected drivers. This gap will be filled by systematically comparing classical and simulation-based MWTs by means of their resulting latencies. In a within-study setup of 36 highly adherent OSA-patients, experiments will be related to a main medical comparator, a ≥7-day continuous positive airway pressure (CPAP)-withdrawal (W) and subsequent -resumption or continuation (C), respectively. There will be a control group of 18 healthy participants for comparison.
Inclusion Criteria (OSA patients): adult drivers, diagnosed OSA, established CPAP-treatment regime, highly adherent and compliant within the last 6 months (>5h, >80% of days), at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)
Inclusion criteria (healthy comparison croup): adult drivers, no declared psychiatric disorders, no declared sleep-related diagnosis, at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)
Exclusion criteria (for both groups): sensibility to motion sickness (kinetosis, dizziness, etc. in 5 min screening drive), professional drivers (if working during the study period), inability to understand the study procedure for linguistic or cognitive reasons.
allocated OSA-participants will perform test sequence M -\> D first after 7d CPAP-withdrawal, then after ≥7d CPAP.
Procedure: CPAP-withdrawal · Diagnostic Test: Test Sequence
allocated OSA-participants will perform test sequence D -\> M first after 7d CPAP-withdrawal, then after ≥7d CPAP.
Procedure: CPAP-withdrawal · Diagnostic Test: Test Sequence
allocated OSA-participants will perform test sequence M -\> D first after ≥7d CPAP, then after 7d CPAP-withdrawal.
Procedure: CPAP-withdrawal · Diagnostic Test: Test Sequence
allocated OSA-participants will perform test sequence D-\> M first after ≥7d CPAP, then after 7d CPAP-withdrawal.
Procedure: CPAP-withdrawal · Diagnostic Test: Test Sequence
healthy participants will perform test sequence M -\> D first , then D -\> M
Diagnostic Test: Test Sequence
healthy participants will perform test sequence D -\> M first , then M -\> D.
Diagnostic Test: Test Sequence
7-day-long CPAP-withdrawal
Test Sequence M or D as specified in arm description
significant difference between mean MWT- and DS-MWT-latencies
significant difference between mean latencies measured in classical maintenance of wakefulness test (MWT, M) and driving simulation-based maintenance of wakefulness test (DS-MWT, D) and DS-MWT-latencies.
Time frame: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.
Plan to share: Yes — Results will be published in peer-reviewed journals. Anonymized raw data will be made available upon request.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: starting after publication of study protcol and/or results
Access criteria: upon request by mail
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Of 32 non-industry interventional studies with no phase under Disorders of Excessive Somnolence, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 21 months is close to that.
Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 7 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Disorders of Excessive Somnolence →
Stefan Lakämper